Grace Therapeutics, Inc.

Grace Therapeutics, Inc. develops and sells products for rare and orphan diseases, aiming to improve patient outcomes through novel drug delivery technologies. The company applies new proprietary formulations to already approved and marketed pharmaceutical compounds. This approach seeks to enhance efficacy, speed up the onset of action, reduce side effects, make drug delivery more convenient, and increase patient compliance. The active pharmaceutical ingredients in its drug candidates may already be approved for a specific use or could be repurposed for new uses. Grace Therapeutics' therapeutic pipeline includes three clinical-stage drug candidates. These candidates are supported by an intellectual property portfolio of more than 79 granted and pending patents across various global jurisdictions. The goal of these drug candidates is to improve clinical outcomes in rare and orphan diseases by applying proprietary formulation and drug delivery technologies to existing pharmaceutical compounds. This aims to either improve upon current standard treatments or provide treatment for diseases that currently lack approved therapies. The company leverages the known efficacy and safety profiles of these marketed compounds, allowing it to use the Section 505(b)(2) regulatory pathway under the Federal Food, Drug and Cosmetic Act (FDCA). This pathway may shorten the time to regulatory approval by potentially reducing the need for some pre-clinical studies and clinical trials, provided sufficient safety and efficacy support can be established through prior FDA experience or existing scientific literature. Grace Therapeutics believes rare disorders offer an attractive area for drug development, and using already approved drugs with established safety profiles and clinical experience can address significant unmet medical needs. Pursuing therapies for rare disorders also offers the potential to receive orphan drug designation (ODD) from the FDA.